Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Palatin Technologies does not have enough data to calculate 5-Year ROIIC %.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Palatin Technologies 5-Year ROIIC % Related Terms
Palatin Technologies 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Palatin Technologies's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KF3 vs BIVI, NCEL, KTTA: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Palatin Technologies's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palatin Technologies 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palatin Technologies's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Palatin Technologies's 5-Year ROIIC % falls into.
Palatin Technologies's 5-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( (Jun. 2025) - (Jun. 2020) )
/
( (Jun. 2025) - (Jun. 2020) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Palatin Technologies (LTS:0KF3) has a 5-Year ROIIC % of -69.21 as of Jun. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Palatin Technologies and its competitors. According to the industry distribution chart, Palatin Technologies ranks #785 out of 1163 companies in the Biotechnology industry, placing it in the top 67.5%.
Is Palatin Technologies' 5-Year ROIIC % too high?
Palatin Technologies' current 5-Year ROIIC % is -69.21. Based on the distribution chart, Palatin Technologies ranks #785 out of 1163 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Palatin Technologies has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Palatin Technologies' 5-Year ROIIC % compare to BIVI and NCEL?
According to the Biotechnology industry distribution chart, Palatin Technologies ranks #785 out of 1163 companies for 5-Year ROIIC %. This places Palatin Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Palatin Technologies and its competitors. Palatin Technologies's current 5-Year ROIIC % is -69.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palatin Technologies stock overvalued right now?
Based on GuruFocus' analysis, Palatin Technologies (LTS:0KF3) is currently considered Possible Value Trap. The stock's GF Value™ is $51.03, compared to a current price of $11.14 — trading 78.2% below its estimated fair value. The current 5-Year ROIIC % is -69.21. Palatin Technologies' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Palatin Technologies (LTS:0KF3), the current 5-Year ROIIC % is -69.21 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Palatin Technologies (LTS:0KF3) Overvalued in 2026?
Based on GuruFocus' analysis, Palatin Technologies stock appears to be undervalued.
The current stock price of $11.14 is trading 78.2% below its estimated GF Value™ of $51.03.
GuruFocus considers Palatin Technologies to be Possible Value Trap.
Key valuation signals for LTS:0KF3:
5-Year ROIIC %: -69.21
GF Value™: $51.03 vs. price of $11.14 (78.2% below fair value)
No single metric tells the full story. See the LTS:0KF3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Palatin Technologies Inc. is a biopharmaceutical company that develops receptor-specific peptide therapeutics based on molecules that modulate the melanocortin receptor system. Its pipeline targets diseases with unmet medical needs, with programs focused on melanocortin-1 receptor (MC1R) agonists for inflammatory and dermatologic conditions and melanocortin-4 receptor (MC4R) agonists for metabolic and other indications. The company's most commercially advanced product is bremelanotide, an MC4R agonist marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women, which was approved by the FDA in 2019 and is licensed to a commercial partner in the United States. Palatin operates in a single business segment, life sciences, and generates revenue primarily through licensing fees, milestone payments, royalties, and collaboration agreements rather than direct product sales. The company is headquartered in Cranbury, New Jersey, and its activities are concentrated in the United States.
45GF Score
Get the complete analysis for LTS:0KF3
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KF3 has been successfully added to your 
